Analyst firms · Morgan Stanley · TXN

Morgan Stanley TXN price target and rating history

Texas Instruments Incorporated (TXN) · Technology

Morgan Stanley rates Texas Instruments Incorporated (TXN) Underweight with a $198 price target, as of its latest action on Jan 26, 2022. It has published 4 rating actions on TXN since July 2021, including 0 upgrades and 0 downgrades. Across 11 firms with a TXN price target in the last 12 months, the median target is $300.

Current rating
Underweight
Price target
$198
Median target, all firms
$300
Actions on TXN
4

Morgan Stanley price target on TXN

$198$192$18520222023202420252026
Morgan Stanley price target on TXN, each point a stated target, July 2021 to January 2022.

Every Morgan Stanley rating on TXN

How other firms rate TXN

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
DZ BankHold$300Oct 28, 2026
Arete ResearchBuy$405Jul 29, 2026
Seaport Research PartnersBuy$400May 22, 2026
MizuhoNeutral$300May 19, 2026
Cantor FitzgeraldNeutral$300May 13, 2026
BofA SecuritiesBuy$320Apr 23, 2026
BarclaysEqual Weight$250Apr 23, 2026
StifelBuy$250Apr 9, 2026
TD CowenBuy$240Jan 28, 2026
BNP Paribas ExaneNeutral$190Jan 22, 2026
Goldman SachsSell$156Dec 15, 2025

Questions about Morgan Stanley and TXN

What is Morgan Stanley's price target for TXN?
Morgan Stanley's latest stated price target for Texas Instruments Incorporated (TXN) is $198, from its action on Jan 26, 2022.
What is Morgan Stanley's rating on TXN?
Morgan Stanley rates TXN Underweight, a bearish rating, as of Jan 26, 2022.
When did Morgan Stanley last change its view on TXN?
On Jan 26, 2022, Morgan Stanley raises its price target to $198 from $195, keeps Underweight.
How does Morgan Stanley's TXN target compare with other analysts?
Across 11 firms with a TXN price target in the last 12 months, the median target is $300.

More TXN rating histories

All Morgan Stanley ratingsTXN news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.